• 1
    Patke DS, Langan SJ, Carruth LM et al. Association of Gag-specific T lymphocyte responses during the early phase of human immunodeficiency virus type 1 infection and lower virus load set point. J Infect Dis 2002; 186:11771180.
  • 2
    Geldmacher C, Currier JR, Herrmann E et al. CD8 T cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients. J Virol 2007; 81:440448.
  • 3
    Foxall RB, Cortesão CS, Albuquerque AS, Soares RS, Victorino RM, Sousa AE. Gag-specific CD4+ T-cell frequency is inversely correlated with proviral load and directly correlated with immune activation in infection with human immunodeficiency virus type 2 (HIV-2) but not HIV-1. J Virol 2008; 82:97959799.
  • 4
    Novitsky V, Gilbert P, Peter T, McLane MF, Gaolekwe S et al. Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection. J Virol 2003; 77:882890.
  • 5
    Addo MM, Yu XG, Rathod A et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003; 77:20812092.
  • 6
    Ostrowski MA, Gu JX, Kovacs C et al. Quantitative and qualitative assessment of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cell immunity to gag in HIV-1-infected individuals with differential disease progression: reciprocal interferon-gamma and interleukin-10 responses. Infect Dis 2001; 184:12681278.
  • 7
    Betts MR, Ambrozak DR, Douek DC et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001; 75:1198311991.
  • 8
    Peretz Y, Alter G, Boisvert MP, Hatzakis G, Tsoukas CM, Bernard NF. Human immunodeficiency virus (HIV)-specific gamma interferon secretion directed against all expressed HIV genes: relationship to rate of CD4 decline. J Virol 2005; 79:49084917.
  • 9
    Peretz Y, Tsoukas CM, Bernard NF. HIV Gag-specific immune responses predict the rate of CD4 decline. AIDS 2008; 22:12221224.
  • 10
    Frahm N, Kiepiela P, Adams S et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 2006; 7:173178.
  • 11
    Kiepiela P, Ngumbela K, Thobakgale C et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. J Nat Med 2007; 13:4653.
  • 12
    Mahlokozera T, Kang HH, Goonetilleke N et al. The magnitude and kinetics of the mucosal HIV-specific CD8+ T lymphocyte response and virus RNA load in breast milk. PLoS ONE 2011; 6:e23735.
  • 13
    Jiao Y, Xie J, Li T et al. Correlation between gag-specific CD8 T-cell responses, viral load, and CD4 count in HIV-1 infection is dependent on disease status. J Acquir Immune Defic Syndr 2006; 42:263268.
  • 14
    Emu B, Sinclair E, Hatano H et al. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol 2008; 82:53985407.
  • 15
    Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:22092220.
  • 16
    Bunce M. PCR-sequence-specific primer typing of HLA class I and class II alleles. Methods Mol Biol 2003; 210:143171.
  • 17
    Argüello JR, Little AM, Bohan E, Goldman JM, Marsh SG, Madrigal JA. High resolution HLA class I typing by reference strand mediated conformation analysis (RSCA). J Tissue Antigens 1998; 52:5766.
  • 18
    Ritchie AJ, Campion SL, Kopycinski J et al. Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals. J Virol 2011; 85:35073516.
  • 19
    Zembe L, Burgers WA, Jaspan HB et al. Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trials. PLoS ONE 2011; 6:e26096.
  • 20
    Goonetilleke N, Liu MK, Salazar-Gonzalez JF et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009; 206:12531272.
  • 21
    Betts MR, Nason MC, West SM et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107:47814789.
  • 22
    Zuñiga R, Lucchetti A, Galvan P et al. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 2006; 80:31223125.
  • 23
    Jiao Y, Xie J, Li T et al. Correlation between gag-specific CD8 T-cell responses, viral load, and CD4 count in HIV-1 infection is dependent on disease status. Acquir Immune Defic Syndr 2006; 42:263268.
  • 24
    Sheth PM, Danesh A, Shahabi K et al. HIV-specific CD8+ lymphocytes in semen are not associated with reduced HIV shedding. J Immunol 2005; 175:47894796.
  • 25
    Gamberg J, Barrett L, Bowmer MI, Howley C, Grant M. Factors related to loss of HIV-specific cytotoxic T lymphocyte activity. AIDS 2004; 18:597604.
  • 26
    Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:61036110.
  • 27
    Ogg GS, Kostense S, Klein MR et al. Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression. J Virol 1999; 73:91539160.
  • 28
    Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, Goepfert PA. Magnitude of functional CD8+ T-cell responses to the Gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 2002; 76:22982305.
  • 29
    van Baalen CA, Pontesilli O, Huisman RC et al. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 1997; 78:19131918.
  • 30
    Rueda CM, Velilla PA, Chougnet CA, Montoya CJ, HIV-induced RMT. T-cell activation/exhaustion in rectal mucosa is controlled only partially by antiretroviral treatment. PLoS ONE 2012; 7:e30307.
  • 31
    García-Arriaza J, Nájera JL, Gómez CE et al. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS ONE 2011; 6:e24244.
  • 32
    Kiepiela P, Ngumbela K, Thobakgale C et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:4653.
  • 33
    Keating SM, Bollinger RC, Quinn TC, Jackson JB, Carruth LM. Cross-clade T lymphocyte-mediated immunity to HIV type 1: implications for vaccine design and immunodetection assays. AIDS Res Hum Retroviruses 2002; 18:10671079.
  • 34
    Martinez-Picado J, Prado JG, Fry EE et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006; 80:36173623.
  • 35
    Sacha JB, Chung C, Rakasz EG et al. Gag specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol 2007; 178:27462754.
  • 36
    Buonaguro L, Tornesello ML, Buonaguro FM. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol 2007; 81:1020910219.
  • 37
    Goulder PJ, Watkins DI. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 2008; 8:619630.
  • 38
    Yusim K, Kesmir C, Gaschen B et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol 2002; 76:87578768.
  • 39
    Briggs JA, Simon MN, Gross I et al. The stoichiometry of Gag protein in HIV-1. Nat Struct Mol Biol 2004; 11:672675.
  • 40
    Kaslow RA, Rivers C, Tang J et al. Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. J Virol 2001; 75:86818689.
  • 41
    Peretz Y, Marra O, Thomas R et al. Relative contribution of HIV-specific functional lymphocyte subsets restricted by protective and non-protective HLA alleles. Viral Immunol 2011; 24:189198.
  • 42
    Boulet S, Bernard NF. Carrying certain KIR3DL1 alleles with HLA-B*57 is associated with protection from HIV infection. Med Sci (Paris) 2008; 24:10301032.
  • 43
    Jin X, Gao X, Ramanathan M Jr et al. Human immunodeficiency virus type 1 (HIV-1)-specific CD8+-T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes. J Virol 2002; 76:1260312610.
  • 44
    Flores-Villanueva PO, Yunis EJ, Delgado JC et al. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc Natl Acad Sci USA 2001; 98:51405145.
  • 45
    Streeck H, Frahm N, Walker BD. The role of IFN-gamma Elispot assay in HIV vaccine research. Nat Protoc 2009; 4:461469.
  • 46
    Olotu A, Moris P, Mwacharo J et al. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria. PLoS ONE 2011; 6:e25786.